China Recalls Contaminated TCM Injection
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China has ordered a recall of two batches of acanthopanax-based injections, also know as Siberian ginseng, after reports of serious adverse reactions that caused the death of three patients in Yunan Province, China's Ministry of Health announced Oct. 11
You may also be interested in...
China Government Report On Drug Regulation Seeks To Increase Transparency
BEIJING - As part of a drive to open China's drug regulatory system to public scrutiny and foster international cooperation, the Chinese government has released a ground-breaking report on the current state of its industry oversight
SFDA Tightens TCM Injection Regulations
China's State Food and Drug Administration recently released the basic technology requirements for traditional Chinese medicine and natural injection to tackle problems in TCM injection such as complicated chemical ingredients, poor preparation technology, shoddy standards, and undeterminate clinical effects. The new regulation requires TCM and natural product injection to identify their ingredients, with single-ingredient TCM injections attaining a purity level of 90 percent. It also seeks to regulate injections with altered route of administration or dosage and better guidelines for generic drugs. Besides imposing more control on non-clinical study and clinical trials, SFDA proposes a surveillance system on adverse drug reactions. Industry observers believe that the stricter regulations will raise TCM production safety and efficacy. (Click here for more
SFDA To Confirm Registrations For All Injectable Drugs
SHANGHAI - China's State Food and Drug Administration will review the registrations of all injectable drugs during the next ten months, and drugs whose manufacturing processes are not in line with their registration documents will have to halt production until the new processes are approved, under a notice issued Aug. 20